Visiongain Report Looks at Opportunities within the $1.8bn Acute Myeloid Leukaemia Market

- Global Acute Myeloid Leukaemia Market Forecast to 2029

- Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

LONDON, Nov. 28, 2019 /PRNewswire/ -- The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 149-page report you will receive 143 charts– all unavailable elsewhere.

The 149-page Visiongain report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-to-2029/#download_sampe_div

Report Scope

• Global Acute Myeloid Leukaemia Market forecast to 2029

• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe
• Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific
• LAMEA: GCC, Brazil, South Africa, Rest of LAMEA

Each national market forecast is further segmented by type: chemotherapy and targeted therapy.

• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva

• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

• This report discusses Porter's Five Forces analysis of the acute myeloid leukaemia market.

• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

• Key questions answered in this report:
• How is the Acute myeloid leukemia market evolving?
• What are the drivers and restraints for the growth of the acute myeloid leukemia market?
• What are the market shares of each segment of the overall acute myeloid leukemia market in 2019?
• How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029?
• What is the value of the leading acute myeloid leukemia segments in important regions of the world?
• What will be the main driver for the overall market from 2019 to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2019 and 2029?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-acute-myeloid-leukaemia-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

AbbVie
Agios Pharmaceuticals, Inc.
Ambit Biosciences Corporation
Amgen
Animas Corporation
Astex
B. Braun Melsungen AG
Baxter, Becton, Dickinson and Company (BD)
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb Company (Bristol-Myers)
Celator Pharmaceuticals, Inc.
Celgene
Clavis Pharma ASA (Clavis Pharma)
Cyclacel
Daiichi Pharmaceutical
Daiichi Sankyo
Eisai Co., Ltd. (Eisai)
F. Hoffmann-La Roche Ltd. (Roche)
Fresenius SE & Co. KGaA
GlaxoSmithKline plc (GSK)
GLOBOCAN
Hospira
Medtronic
Moog Inc.
NeoMed
Norsk Hydro
Novartis
Onyx Pharmaceuticals
Sankyo
Seattle Genetics
Smiths Group Plc.,
Sunesis Pharmaceuticals, Inc. (Sunesis)
TEVA Pharmaceutical Industries Limited (TEVA)

List of Organizations Mentioned in the Report
American Cancer Organization
Baylor Scott and White Research Institute
Benaroya Research Institute at Virginia Mason
Beth Israel Deaconess Medical Center
Breslin Cancer Center
Center for Blood Disorders and Stem Cell Transplantation
Charles A. Sammons Cancer Center
Columbia University Medical
Dana Farber Cancer Institute
Duke Cancer Center
European Commission
Fred Hutchinson Cancer Research Center
Health Canada
Herbert Irving Comprehensive Cancer Center
Institute of Hematology & Blood Diseases Hospital,Tianjin
James Graham Brown Cancer Center
Legacy Emanuel Hospital & Health Center
Mary Babb Randolph Cancer Center
Massachusetts general Hospital
Mayo Clinic
MD Anderson Cancer Center
Medical College of Wisconsin Cancer Center
Medizinische Klinik und Poliklinik I
Memorial Sloan Kettering Cancer Center
Michigan State University
Nantes University Hospital
National Cancer Institute
New Jersey Hematology Oncology Associates
Northwestern University
Ochsner Medical Center
Penn State Hershey Cancer Institute-Clinical Trials Office
Perelman Center for Advanced Medicine
Princess Margaret Hospital
St. Francis Cancer Center
St. Joseph Mercy Hospital
St. Vincent's Comprehensive Cancer Center
Swedish Cancer Institute
The Gayle and Tom Benson Cancer Center
The University of Hong Kong
The University of Iowa
The University of Texas MD Anderson Cancer Center
Thomas Jefferson University
U.S. Food and Drug Administration (FDA)
UCLA Medical Center, Division of Hematology/Oncology
University Hospital, Caen
University of Kansas Cancer Center
University of Kansas Medical Center Research Institute
University of Kentucky
University of Louisville
University of Michigan Health System
University of Pennsylvania
University of Texas M.D. Anderson Cancer Center
VA Caribbean Healthcare System
Weill Cornell Medical College
Weill Medical College of Cornell University
West Virginia University
World Health Organization (WHO)

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Biosimilars and Follow-On Biologics Market 2019-2029

Global Protein Expression Market Forecast to 2029

Top 25 Biosimilar Drug Manufacturers 2019

Global Diagnostic Imaging Market Forecast 2019-2029

Global Oncology Pricing, Reimbursement & Market Access 2019-2029 

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg